PT  - JOURNAL ARTICLE
AU  - Hoertel, N.
AU  - Sánchez-Rico, M.
AU  - Gulbins, E.
AU  - Kornhuber, J.
AU  - Vernet, R.
AU  - Beeker, N.
AU  - Neuraz, A.
AU  - Blanco, C.
AU  - Olfson, M.
AU  - Airagnes, G.
AU  - Lemogne, C.
AU  - Alvarado, J. M.
AU  - Arnaout, M.
AU  - Meneton, P.
AU  - Limosin, F.
AU  - ,
TI  - Association between benzodiazepine receptor agonist use and increased mortality among patients hospitalized for COVID-19: results from an observational study
AID  - 10.1101/2021.02.18.21252004
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.02.18.21252004
4099  - http://medrxiv.org/content/early/2021/02/20/2021.02.18.21252004.short
4100  - http://medrxiv.org/content/early/2021/02/20/2021.02.18.21252004.full
AB  - Objective To examine the association between benzodiazepine receptor agonist (BZRA) use and mortality in patients hospitalized for COVID-19.Methods We conducted an observational multicenter retrospective cohort study at AP-HP Greater Paris University hospitals. The sample involved 14,381 adult patients hospitalized for COVID-19. 686 (4.8%) inpatients received a BZRA within at the time of hospital admission at a mean daily diazepam-equivalent dose of 19.7 mg (SD=25.4). The study baseline was the date of hospital admission and the primary endpoint was death. We compared this endpoint between patients who received BZRAs and those who did not in time-to-event analyses adjusted for patient characteristics (such as age, sex, obesity and comorbidity) and other medications. The primary analysis was a Cox regression model with inverse probability weighting (IPW).Results Over a mean follow-up of 14.5 days (SD=18.1), the primary endpoint occurred in 186 patients (27.1%) who received a BZRA and in 1,134 patients (8.3%) who did not. There was a significant association between BZRA use and increased mortality both in the crude analysis (HR=3.20; 95% CI=2.74-3.74; p<0.01) and in the primary IPW analysis (HR=1.61; 95% CI=1.31-1.98, p<0.01), with a significant dose-dependent relationship (HR=1.55; 95% CI=1.08-2.22; p=0.02). This association remained significant in multiple sensitivity analyses.Conclusions BZRA use was associated with increased mortality among patients hospitalized for COVID-19 with a dose-dependent relationship, suggesting a potential benefit of decreasing dose or tapering off these medications when possible in these patients.Competing Interest StatementDr Hoertel has received personal fees and non-financial support from Lundbeck, outside the submitted work. Dr Limosin has received speaker and consulting fees from Janssen-Cilag outside the submitted work. Dr Lemogne reports personal fees and non-financial support from Janssen-Cilag, Lundbeck, Otsuka Pharmaceutical, and Boehringer Ingelheim, outside the submitted work. Dr Airagnes reports personal fees from Pfizer, Pierre Fabre and Lundbeck, outside the submitted work. Other authors declare no competing interests.Funding StatementThis work did not receive any external funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This observational study using routinely collected data received approval from the Institutional Review Board of the AP-HP clinical data warehouse (decision CSE-20- 20_COVID19, IRB00011591). AP-HP clinical Data Warehouse initiatives ensure patient information and informed consent regarding the different approved studies through a transparency portal in accordance with European Regulation on data protection and authorization no. 1980120 from National Commission for Information Technology and Civil Liberties (CNIL). All procedures related to this work adhered to the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData from the AP-HP Health Data Warehouse can be obtained with permission at https://eds.aphp.fr//. https://eds.aphp.fr//